FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319160354> ?p ?o ?g. }

• W4319160354 endingPage "1379" @default.
• W4319160354 startingPage "1368" @default.
• W4319160354 abstract "Biotherapies targeting IL-5 allow a tangible improvement of asthma. However, all patients do not respond the same way to these treatments. Even if high blood eosinophil counts seem to be associated with a reduction in exacerbations with treatment targeting IL-5, we lack biomarkers for the prediction of remission after these very expensive treatments.Are there biomarkers of remission after therapy targeting IL-5 in the sputum of patients with severe eosinophilic asthma?This observational study included 52 patients with severe asthma initiated with anti-IL-5 therapy and recruited from the asthma clinic of the Centre Hospitalier Universitaire of Liege, Belgium. Remission was defined as patients who combined the following at 1 year after therapy: no chronic treatment with oral corticosteroids; no exacerbation; asthma control questionnaire score < 1.5, asthma control test score > 19, or both; FEV1 of ≥ 80% predicted, improvement of FEV1 of ≥ 10%, or both; and a blood eosinophil count < 300 cells/μL. Eosinophil peroxidase (EPX), IgE, IL-3, IL-4, IL-5, IL-13, IL-25, IL-33, granulocyte-macrophage colony-stimulating factor, thymic stromal lymphopoietin (TSLP), and eotaxin-1 levels were measured in the sputum of these patients before anti-IL-5 treatment.Among the 52 patients, 11 were classified as being in remission. These patients were characterized by higher sputum eosinophil, macrophage, and lymphocyte counts, whereas the sputum neutrophil percentage was lower than in the nonremission group. In addition, the sputum eotaxin-1, TSLP, IL-5, EPX, and IgE protein levels were higher at baseline in the remission group compared with the nonremission group. Univariate regression analysis revealed that male vs female sex, sputum neutrophil percentage, eotaxin-1, IL-5, and EPX were potential predictors of remission.Sputum type 2 markers seemed to be potentially predictive of remission after anti-IL-5 therapy in a cohort of patients with severe eosinophilic asthma. These results need validation on a larger cohort." @default.
• W4319160354 created "2023-02-04" @default.
• W4319160354 creator A5022924667 @default.
• W4319160354 creator A5030456446 @default.
• W4319160354 creator A5037900167 @default.
• W4319160354 creator A5038686952 @default.
• W4319160354 creator A5042160285 @default.
• W4319160354 creator A5048774541 @default.
• W4319160354 creator A5058284074 @default.
• W4319160354 creator A5058946302 @default.
• W4319160354 creator A5070838971 @default.
• W4319160354 creator A5084086966 @default.
• W4319160354 creator A5085151472 @default.
• W4319160354 creator A5087596866 @default.
• W4319160354 creator A5089411513 @default.
• W4319160354 date "2023-06-01" @default.
• W4319160354 modified "2023-10-18" @default.
• W4319160354 title "Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5" @default.
• W4319160354 cites W1973694446 @default.
• W4319160354 cites W2039849310 @default.
• W4319160354 cites W2094189191 @default.
• W4319160354 cites W2098276532 @default.
• W4319160354 cites W2105707546 @default.
• W4319160354 cites W2125078269 @default.
• W4319160354 cites W2154766995 @default.
• W4319160354 cites W2370552689 @default.
• W4319160354 cites W2755334065 @default.
• W4319160354 cites W2994812624 @default.
• W4319160354 cites W3007357419 @default.
• W4319160354 cites W3009509122 @default.
• W4319160354 cites W3011055151 @default.
• W4319160354 cites W3015924558 @default.
• W4319160354 cites W3027043096 @default.
• W4319160354 cites W3093042321 @default.
• W4319160354 cites W3094710424 @default.
• W4319160354 cites W3169952663 @default.
• W4319160354 cites W4220906590 @default.
• W4319160354 doi "https://doi.org/10.1016/j.chest.2023.01.037" @default.
• W4319160354 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36740095" @default.
• W4319160354 hasPublicationYear "2023" @default.
• W4319160354 type Work @default.
• W4319160354 citedByCount "6" @default.
• W4319160354 countsByYear W43191603542023 @default.
• W4319160354 crossrefType "journal-article" @default.
• W4319160354 hasAuthorship W4319160354A5022924667 @default.
• W4319160354 hasAuthorship W4319160354A5030456446 @default.
• W4319160354 hasAuthorship W4319160354A5037900167 @default.
• W4319160354 hasAuthorship W4319160354A5038686952 @default.
• W4319160354 hasAuthorship W4319160354A5042160285 @default.
• W4319160354 hasAuthorship W4319160354A5048774541 @default.
• W4319160354 hasAuthorship W4319160354A5058284074 @default.
• W4319160354 hasAuthorship W4319160354A5058946302 @default.
• W4319160354 hasAuthorship W4319160354A5070838971 @default.
• W4319160354 hasAuthorship W4319160354A5084086966 @default.
• W4319160354 hasAuthorship W4319160354A5085151472 @default.
• W4319160354 hasAuthorship W4319160354A5087596866 @default.
• W4319160354 hasAuthorship W4319160354A5089411513 @default.
• W4319160354 hasBestOaLocation W43191603541 @default.
• W4319160354 hasConcept C126322002 @default.
• W4319160354 hasConcept C142724271 @default.
• W4319160354 hasConcept C203014093 @default.
• W4319160354 hasConcept C2776042228 @default.
• W4319160354 hasConcept C2776301714 @default.
• W4319160354 hasConcept C2777014857 @default.
• W4319160354 hasConcept C2777037409 @default.
• W4319160354 hasConcept C2777716647 @default.
• W4319160354 hasConcept C2779758542 @default.
• W4319160354 hasConcept C2781069245 @default.
• W4319160354 hasConcept C71924100 @default.
• W4319160354 hasConcept C88675164 @default.
• W4319160354 hasConcept C90924648 @default.
• W4319160354 hasConceptScore W4319160354C126322002 @default.
• W4319160354 hasConceptScore W4319160354C142724271 @default.
• W4319160354 hasConceptScore W4319160354C203014093 @default.
• W4319160354 hasConceptScore W4319160354C2776042228 @default.
• W4319160354 hasConceptScore W4319160354C2776301714 @default.
• W4319160354 hasConceptScore W4319160354C2777014857 @default.
• W4319160354 hasConceptScore W4319160354C2777037409 @default.
• W4319160354 hasConceptScore W4319160354C2777716647 @default.
• W4319160354 hasConceptScore W4319160354C2779758542 @default.
• W4319160354 hasConceptScore W4319160354C2781069245 @default.
• W4319160354 hasConceptScore W4319160354C71924100 @default.
• W4319160354 hasConceptScore W4319160354C88675164 @default.
• W4319160354 hasConceptScore W4319160354C90924648 @default.
• W4319160354 hasFunder F4320307770 @default.
• W4319160354 hasFunder F4320307773 @default.
• W4319160354 hasFunder F4320309888 @default.
• W4319160354 hasIssue "6" @default.
• W4319160354 hasLocation W43191603541 @default.
• W4319160354 hasLocation W43191603542 @default.
• W4319160354 hasOpenAccess W4319160354 @default.
• W4319160354 hasPrimaryLocation W43191603541 @default.
• W4319160354 hasRelatedWork W1997095217 @default.
• W4319160354 hasRelatedWork W1997827344 @default.
• W4319160354 hasRelatedWork W2014078838 @default.
• W4319160354 hasRelatedWork W2053208368 @default.
• W4319160354 hasRelatedWork W2055390361 @default.
• W4319160354 hasRelatedWork W2137811314 @default.

• next